Alliqua BioMedical, Inc. (NASDAQ:ALQA) reported Q2 2017 earnings this Morning, coming in at ($0.09) per share, beating Wall Street’s estimates of ($0.14) per Share. Revenue for the quarter came in at $5.52 million beating analyst estimates of $5.01 million
Analyst Coverage For Alliqua BioMedical, Inc. (NASDAQ:ALQA)
These are 3 Buy Ratings .
The current consensus rating for Alliqua BioMedical, Inc. (NASDAQ:ALQA) is Buy (Score: 3.00) with a consensus target price of $1.42 , a potential (304.76% upside)Recent Insider Trading for Alliqua BioMedical, Inc. (NASDAQ:ALQA)
- On 4/3/2017 Bradford Barton, COO, bought 75,000 with an average share price of $0.40 per share and the total transaction amounting to $30,000.00.
- On 4/3/2017 David Ian Johnson, Insider, bought 250,000 with an average share price of $0.40 per share and the total transaction amounting to $100,000.00.
- On 4/3/2017 Mark T Wagner, Director, bought 62,500 with an average share price of $0.40 per share and the total transaction amounting to $25,000.00.
- On 2/27/2017 Corp /De/ Celgene, Major Shareholder, bought 4,000,000 with an average share price of $0.50 per share and the total transaction amounting to $2,000,000.00.
- On 2/27/2017 Jerome B Zeldis, Director, bought 400,000 with an average share price of $0.50 per share and the total transaction amounting to $200,000.00.
- On 11/9/2015 Brian M Posner, CFO, bought 5,000 with an average share price of $3.04 per share and the total transaction amounting to $15,200.00.
Recent Trading for Alliqua BioMedical, Inc. (NASDAQ:ALQA) Shares of Alliqua BioMedical, Inc. closed the previous trading session at 0.300 down -0.050 -14.37% with 72,122 shares trading hands.